LOS ANGELES — The novel phosphodiesterase 10A (PDE10A) inhibitor known as CPL’36 (Celon Pharma) is effective and generally safe in acute exacerbations of schizophrenia, new research suggested.
In a phase 2 trial of 189 patients with acute schizophrenia, compared with the placebo group, the groups receiving CPL’36 20 or 40 mg once daily both met the primary endpoint of a significant improvement from baseline to day 28 in scores on the positive subscale of the Positive and Negative Syndrome Scale (PANSS).
Both active treatment groups also showed a significant improvement in total scores on the PANSS, and the 40-mg group showed a significant improvement in scores on the negative subscale of the PANSS.
The most commonly reported adverse events for all groups included…